Regional non-small cell lung cancer summits


Engaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment (GAIN) is an educational curriculum designed for health-care providers to improve their knowledge, skills, and competence in the assessment and management of non-small cell lung cancer (NSCLC).

About GAIN

GAIN Live Summits feature experiential learning; theory-based instructional design with pre-course learning activities; flipped classroom; and interactive, participatory group, and team-based workshop sessions for pulmonology, thoracic surgery, pathology, and oncology clinicians.

Until recently, therapy in advanced NSCLC has been primarily cytotoxic chemotherapy. Now, new information about the molecular origins of cancer, which has been incorporated into the overall approach of targeted therapy, has led to a very complex therapeutic landscape. 

Also, obtaining adequate tissue samples and performing appropriate testing and analysis of various molecular markers require engagement of an interdisciplinary medical team leading to the identification of optimal therapeutic options, including monoclonal antibodies (MAbs), tyrosine kinase inhibitors (TKIs), and traditional cytotoxic chemotherapy.

Content addresses management of locally advanced and metastatic lung cancer by using multidisciplinary and multimodality approaches. These include conventional chemotherapy and biomarker-driven therapy, including immune checkpoint inhibitors that target to unleash or enhance pre-existing anticancer immune responses. 

Examples of these immunotherapies target PD-1 antibodies, PD-L1 antibodies, and CTLA-4 antibodies. Genotype-driven therapy will be addressed by discussing agents that target genetic abnormalities, including but not limited to: EGFR, KRAS, and BRAF mutations and ALK and ROS1 translocations.


Published Outcomes

Outcomes from the GAIN program are published in the​ journal​ CHEST®. Analysis of the program data support​s​ how highly successful the program is in improving knowledge, competence,​ and clinical care provided to patients with NSCLC.

View Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams in the CHEST Journal.

Target Audience

This initiative will engage the following healthcare professional audiences who focus on NSCLC diagnosis and patient care:


Past GAIN Events 

Washington DC | November 12, 2016
Tampa, FL | January 14,  2017
Atlanta, GA | February 11, 2017
San Francisco, CA | March 11, 2017
St. Louis, MO | April 22, 2017
Houston, TX | April 29, 2017
Pittsburgh, PA | May 13, 2017 

Steering Committee

Eric Edell, MD, FCCP - Chair
Professor of Medicine
Mayo Clinic College of Medicine
Mayo Clinic Rochester
Rochester, MN

Septimiu Murgu, MD, FCCP - Chair
Associate Professor of Medicine
Co-Director of Bronchoscopy
Program Director, Interventional Pulmonology Fellowship
The University of Chicago Medicine
Chicago, IL

David Ettinger, MD, FCCP
Alex Grass Professor of Oncology
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Baltimore, MD

Rudy P. Lackner, MD, FCCP
Professor of Surgery
Chief, Thoracic Surgery
Director, Residency Program in Cardiothoracic Surgery
University of Nebraska Medical Center
Omaha, NE

Mari Mino-Kenudson, MD
Pulmonary Pathology Service, Massachusetts General Hospital
Associate Professor of Pathology, Harvard Medical School
Boston, MA

This activity is supported by educational grants from Merck and AstaZeneca.

Copyright 2019 © American College of Chest Physicians®

Printed from: